Drug intelligence / Profile preview

rLCMV-TRP2

Development stage: Preclinical
Lead developer: HOOKIPA Pharma
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

rLCMV-TRP2 is a recombinant, non-replicating viral vector-based cancer vaccine constructed using the lymphocytic choriomeningitis virus (LCMV) backbone to express the tumor-associated antigen **TRP2** (tyrosinase-related protein 2)[3]. Designed as an immunotherapy for melanoma, its mechanism of action is to elicit TRP2-specific CD8^+^ T-cell responses to target and eradicate TRP2-expressing melanoma cells[1][3]. However, rLCMV-TRP2 is notably less effective at breaking immune tolerance and inducing strong antitumor T-cell responses compared to replicating LCMV-based TRP2 vaccines (artLCMV-TRP2)[1][3].

Other names: rLCMV-TRP2rLCMV-TRP-2rLCMV-TRP 2

Targets

TYRP2 (Tyrosinase-related Protein 2)α-DG (Alpha-dystroglycan)

Beyond the preview

Go deeper on rLCMV-TRP2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rLCMV-TRP2.

Explore the full profile